|
DK3286181T3
(da)
|
2015-04-22 |
2021-04-06 |
Rigel Pharmaceuticals Inc |
Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne
|
|
CN108884077A
(zh)
*
|
2016-02-25 |
2018-11-23 |
阿森纽荣股份公司 |
糖苷酶抑制剂
|
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
|
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
|
CN110099899B
(zh)
|
2016-10-26 |
2024-01-02 |
里格尔药品股份有限公司 |
用作irak抑制剂的噁唑衍生物及其制备方法
|
|
CN110234637B
(zh)
|
2016-10-26 |
2022-11-01 |
里格尔药品股份有限公司 |
用作irak抑制剂的吡唑酰胺化合物
|
|
AU2017363313B2
(en)
*
|
2016-11-22 |
2021-06-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
|
|
WO2018142393A1
(en)
|
2017-02-01 |
2018-08-09 |
Yissum Research Development Company Of The Hebrew |
N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer
|
|
TW202340194A
(zh)
|
2017-02-16 |
2023-10-16 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
EP3620457A4
(en)
*
|
2017-05-02 |
2021-01-06 |
Korea Research Institute of Chemical Technology |
PYRIMIDE-DERIVATIVE COMPOUND, OPTICAL ISOMER THEREOF, OR PHARMACEUTICAL SALT THEREOF AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYRO-3 RELATED DISEASES THEREOF AS ACTIVE SUBSTANCE
|
|
WO2019008506A1
(en)
*
|
2017-07-03 |
2019-01-10 |
Glaxosmithkline Intellectual Property Development Limited |
N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
|
|
IL301709B2
(en)
*
|
2017-08-09 |
2025-07-01 |
Denali Therapeutics Inc |
Compounds, compositions and methods
|
|
TW201920129A
(zh)
|
2017-09-01 |
2019-06-01 |
美商戴納立製藥公司 |
化合物、組合物及方法
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
TWI721483B
(zh)
|
2018-07-13 |
2021-03-11 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
TWI727392B
(zh)
|
2018-08-13 |
2021-05-11 |
美商基利科學股份有限公司 |
噻二唑irak4抑制劑
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP3924341A4
(en)
|
2019-02-13 |
2022-11-02 |
Denali Therapeutics Inc. |
Compounds, compositions and methods
|
|
CR20210426A
(es)
|
2019-02-13 |
2021-09-30 |
Denali Therapeutics Inc |
Compuestos, composiciones y métodos
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
JP2022545542A
(ja)
|
2019-08-30 |
2022-10-27 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
TW202241857A
(zh)
|
2020-12-18 |
2022-11-01 |
美商戴納立製藥公司 |
化合物之固體形式
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
WO2022187303A1
(en)
|
2021-03-03 |
2022-09-09 |
Rigel Pharmaceuticals, Inc. |
A method for treating a disease or condition using a pyrazole compound or formulation thereof
|
|
WO2022217118A1
(en)
*
|
2021-04-09 |
2022-10-13 |
Quanta Therapeutics, Inc. |
Pyrimidine based ras modulators and uses thereof
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその合成
|
|
CN116514769B
(zh)
*
|
2022-01-21 |
2024-02-27 |
中国药科大学 |
4-羟基嘧啶-5-甲酰腙衍生物、制备方法、药物组合物和应用
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
CA3243798A1
(en)
|
2022-02-09 |
2023-08-17 |
Quanta Therapeutics, Inc. |
Kras Modulators and Their Uses
|
|
ES3075943T3
(en)
|
2022-03-23 |
2026-08-10 |
Rigel Pharmaceuticals Inc |
Pyrimid-2-yl-pyrazole compounds as irak inhibitors
|
|
WO2023230190A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics, Inc. |
Pyrimidine based modulators and uses thereof
|
|
EP4680609A1
(en)
|
2023-03-15 |
2026-01-21 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
CN117924102B
(zh)
*
|
2024-01-23 |
2026-06-26 |
四川伊诺唯新生物医药有限公司 |
一种微管亲和力调节激酶抑制剂中间体的制备方法
|